In Vitro Evolution of Ligands to the Membrane Protein Caveolin

详细信息    查看全文

• 作者：Sudipta Majumdar ; Agnes Hajduczki ; Rosemarie Vithayathil ; Tivoli J. Olsen ; Ryan M. Spitler ; Aaron S. Mendez ; Travis D. Thompson ; Gregory A. Weiss
• 刊名：Journal of the American Chemical Society
• 出版年：2011
• 出版时间：June 29, 2011
• 年：2011
• 卷：133
• 期：25
• 页码：9855-9862
• 全文大小：1020K
• 年卷期：v.133,no.25(June 29, 2011)
• ISSN：1520-5126

文摘

Membrane proteins comprise a third of the human genome, yet present challenging targets for reverse chemical genetics. For example, although implicated in numerous diseases including multiple myeloma, the membrane protein caveolin-1 appears to offer a poor target for the discovery of synthetic ligands due to its largely unknown structure and insolubility. To break this impasse and identify new classes of caveolae controlling lead compounds, we applied phage-based, reverse chemical genetics for the discovery of caveolin-1 ligands derived from the anti-HIV therapeutic T20. Substitution of homologous residues into the T20 sequence used a process analogous to medicinal chemistry for the affinity maturation to bind caveolin. The resultant caveolin-1 ligands bound with >1000-fold higher affinity than wild-type T20. Two types of ELISAs and isothermal titration calorimetry (ITC) measurements demonstrated high affinity binding to caveolin by the T20 variants with K_d values in the 150 nM range. Microscopy experiments with the highest affinity caveolin ligands confirmed colocalization of the ligands with endogenous caveolin in NIH 3T3 cells. The results establish the foundation for targeting caveolin and caveolae formation in living cells.